METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF METOPROLOL AND ATORVASTATIN BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY IN ITS BULK AND PHARMACEUTICAL TABLET DOSAGE FORM USING BIORELEVANT DISSOLUTION MEDIA (FASTED STATE SMALL INTESTINAL FLUID)

Authors

  • Palani Shanmugasundaram 1Department of , School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India
  • Kamarapu Sk2 Department Pharmaceutical Analysis, School Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11s4.31675

Keywords:

Metoprolol and atorvastatin, Reversed-phase high-performance liquid chromatography, Method development, Validation, International Conference on Harmonisation Q2 (R1), Biorelevant dissolution media (fasted state small intestinal fluid)

Abstract

Objective: A present investigation is based on method development and validation for the simultaneous determination of metoprolol and atorvastatin by reversed-phase high-performance liquid chromatography in its bulk and pharmaceutical dosage form using a biorelevant dissolution media (fasted state small intestinal fluid).

Methods: The chromatographic separation technique performed by an isocratic method for this column used Inertsil ODS-3 (4.6×150 mm, 5 μm). The ratio of mobile phase used is phosphate buffer 4.8 pH: acetonitrile (35:65v/v), flow rate 1 ml/min, and analysis time 15.0 min, UV detection was at 244 nm.

Results: According to the International Conference on Harmonisation Q2 (R1) guidelines, the method validation was done. Peaks were observed at 2.227 min and 5.819 min, concentration range of linearity was obtained at 50–250 μg/ml and 10–50 μg/ml, linearity correlation coefficients were 0.9997 and 0.9995, limit of detection was 0.33 mg/ml and 0.21 mg/ml, and limit of quantification was 1.08 mg/ml and 0.69 mg/ml for metoprolol and atorvastatin, respectively.

Conclusion: The obtained results for this method validation are within acceptance criteria. This method was more economical and stable for routine analysis.

Downloads

Download data is not yet available.

References

Schäfer M, Frischkopf K, Taimor G, Piper HM, Schlüter KD. Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am J Physiol Cell Physiol 2000;279:C495-503.

Ladage D, Schwinger RH, Brixius K. Cardio-selective beta-blocker: Pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther 2013;31:76-83.

Staudt A, Mobini R, Fu M, Grosse Y, Stangl V, Stangl K, et al. Beta(1)- adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharmacol 2001;423:115-9.

Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, et al. Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008;84:715-21.

Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003;74:372-9.

Jafari M, Ebrahimi R, Ahmadi-Kashani M, Balian H, Bashir M. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther 2003;8:123-6.

Baxter JD, Webb P, Grover G, Scanlan TS. Selective activation of thyroid hormone signaling pathways by GC-1: A new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 2004;15:154-7.

Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, et al. Effect of pitavastatin on apolipoprotein A-I production in hepG2 cell. Biochem Biophys Res Commun 2004;324:835-9.

Bösel J, Gandor F, Harms C, Synowitz M, Harms U, Djoufack PC, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005;92:1386-98.

Chen X, Ji ZL, Chen YZ. TTD: Therapeutic target database. Nucleic Acids Res 2002;30:412-5.

Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken, New Jersey: Wiley Publishers; 2010.

Sangshetti JN, Aqeel M, Zaheer Z, Ahmed RZ, Dehghan MH, Gonjari I. Development and validation of RP-HPLC method for determination of atorvastatin calcium and nicotinic acid in combined tablet dosage form. J Saudi Chem Soc 2016;20:S328-33.

Peraman R, Mallikarjuna S, Ammineni P, Kondreddy VK. RP-HPLC method development and validation for simultaneous estimation of atorvastatin calcium and pioglitazone hydrochloride in pharmaceutical dosage form. J Chromatogr Sci 2014;52:1038-42.

Kurakula M, Sobahi TR, El-Helw AM, Abdelaal MY. Development and validation of an RP-HPLC method for assay of atorvastatin and its application in dissolution studies on thermosensitive hydrogel-based nanocrystals. Trop J Pharm Res 2014;13:1681-7.

Sharma R, Khanna S, Mishra GP. Development and validation of RP-HPLC method for simultaneous estimation of ramipril, aspirin and atorvastatin in pharmaceutical preparations. E-J Chem 2012;9:2177-84.

Jain N, Raghuwanshi R, Jain D. Development and validation of RP-HPLC method for simultaneous estimation of atorvastatin calcium and fenofibrate in tablet dosage forms. Indian J Pharm Sci 2008;70:263-5.

Raul SK, Aravelli AB, Jhansi D. RP-HPLC method development and validation for the simultaneous estimation of atorvastatin and ezetimibe in pharmaceutical dosage form. Asian J Pharm Clin Res 2015;8:178-81.

Mawazi SM, Reddy GN. Method development and validation for simultaneous estimation of atorvastatin and ezetimibe in pharmaceutical dosage form by HPLC. World J Pharm Sci 2014;2:866-70.

Kumar SA, Debnath M, Rao JV, Sankar DG. New validated stability-indicating rp-HPLC method for simultaneous estimation of atorvastatin and ezetimibe in human plasma by using PDA detector. Adv Pharm Bull 2015;5:385-91.

Pryanka J, Mukesh K. Development and validation of a reverse phase HPLC method for the simultaneous estimation of metoprolol and telmisartan in tablet dosage form. Pharm Sin 2011;2:211-9.

Venkateswararao L, Vardhan SV, Venkatrao SV, Chintala R. Validated RP-HPLC method for the estimation of metoprolol succinate in dosage formulations. Am J Pharmtech Res 2013;3:328-34.

Nilesh J, Kumar SB, Ruchi J, Kumar JD, Surendra J. RP-HPLC method development and validation for quantitative estimation of metoprolol succinate and telmisartan in bulk drug and their dosage forms. J Pharm Biomed Sci 2012;24:102-6.

Brijesh S, Patel DK, Ghosh SK. Development of reverse-phase HPLC method for simultaneous analysis of metoprolol succinate and hydrochlorothiazide in a tablet formulation. Trop J Pharm Res 2009;8:539-43.

Tsvetkova BG, Pencheva IP, Peikov PT. Development and validation of RP-HPLC method for simultaneous determination of metoprolol and aspirin in fixed dose combinations. Pharm Chem 2012;4:1512-6.

Pokala M, Rani PJ, Pranathi G, Haque MA, Sireesha D, et al. Development and validation of rp-hplc method for the simultaneous estimation of amlodipine and metoprolol in bulk and pharmaceutical dosage form. Indo Am J Pharm Res 2015;5:3254-60.

Madhukar A, Kannappan N. RP-HPLC method for the simultaneous estimation of cilnidipine and metoprolol succinate in bulk and tablet dosage form in biorelevant media (FaSSIF). Int J Pharm Tech Res 2015;7:172-84.

Marques M. Dissolution media simulating fasted and fed states. Dissolut Technol 2004;11:16.

Nitin BB, Adhikrao VY, Sachin SM, Rohan AK, Ashok AH, Sachin SS, et al. A review on development of biorelevant dissolution medium. J Drug Deliv Ther 2014;4:140-8.

Sharma MK. Bio-relevant dissolution media development. J Bioequiv Availab 2016;9:1-2.

Kostewicz ES, Brauns U, Becker R, Dressman JB. Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media. Pharm Res 2002;19:345-9.

Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000;11 Suppl 2:S73-80.

ICH. Validation of Analytical Procedures: Text and Methodology Q2 (R1). International Conference on Harmonization; 2005.

Published

28-12-2018

How to Cite

Shanmugasundaram, P., and K. Sk2. “METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF METOPROLOL AND ATORVASTATIN BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY IN ITS BULK AND PHARMACEUTICAL TABLET DOSAGE FORM USING BIORELEVANT DISSOLUTION MEDIA (FASTED STATE SMALL INTESTINAL FLUID)”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 16, Dec. 2018, pp. 54-61, doi:10.22159/ajpcr.2018.v11s4.31675.

Issue

Section

Original Article(s)